Orikine Bio

Executive Summary

Orikine Bio is a Barcelona-based biotechnology company pioneering precision-engineered bi-specific cytokine therapies for autoimmune and inflammatory diseases. Founded in 2021 as a spin-off from the Centre for Genomic Regulation (CRG), the company leverages its proprietary Foldikine™ platform to create cytokine 'patches' that reprogram faulty immune signaling. The platform enables the design of bi-specific molecules with enhanced specificity and reduced toxicity, addressing key limitations of conventional cytokine therapies. Orikine is currently in preclinical development, advancing a pipeline of candidates for indications such as rheumatoid arthritis and inflammatory bowel disease. The company's innovative approach and strong scientific foundation position it as a promising player in the biologics space, though it remains at an early stage with no publicly disclosed funding rounds or clinical data.

Upcoming Catalysts (preview)

• Q3 2026Series A financing round70% success
• Q4 2026Lead development candidate nomination60% success
• Q1 2027Preclinical proof-of-concept data release50% success